Polyclonal antibodies against the human cell surface CD34 marker

Yu. S. Nikolaiev(Taras Shevchenko National University of Kyiv), В. А. Кордюм, Pavlo Gilchuk(AstraZeneca (Japan)), Д. М. Іродов(National Academy of Sciences of Ukraine), Д. В. Колибо(Palladin Institute of Biochemistry), А. J. Labyntsev(National Academy of Sciences of Ukraine), Andrew I. Flyak(Vanderbilt University), O. B. Gorbatiuk(Institute of Molecular Biology and Genetics)
Cytology and Genetics
June 1, 2011
10.3103/s0095452711030066
Cited by 0

Related Papers

Potently neutralizing and protective human antibodies against SARS-CoV-2
|Nature|2020|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
|Nature Medicine|2020|543
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
|Cell|2021|409